Victoria M. Catterson
University of Strathclyde
H-index: 24
Europe-United Kingdom
Top articles of Victoria M. Catterson
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Drivers of mortality in COVID ARDS depend on patient sub-type | Computers in Biology and Medicine | Helen Cheyne Amir Gandomi Shahrzad Hosseini Vajargah Victoria M Catterson Travis Mackoy | 2023/11/1 |
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’trial | Thorax | Zelalem Temesgen Colleen F Kelley Frank Cerasoli Adrian Kilcoyne Dale Chappell | 2023/6/1 |
Phenotype-driven identification of drug targets for post-COVID-19 anosmia | bioRxiv | Victoria M Catterson Yolanda Sanchez Gabriel Musso | 2022/8/4 |
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial | The Lancet Respiratory Medicine | Zelalem Temesgen Charles D Burger Jason Baker Christopher Polk Claudia R Libertin | 2022/3/1 |
Early lenzilumab treatment of COVID-19 patients using c-reactive protein as a biomarker improves efficacy: results from the phase 3 ‘LIVE-AIR’trial | MedRxiv | Zelalem Temesgen Colleen F Kelley Franklin Cerasoli Adrian Kilcoyne Dale Chappell | 2022/1/1 |
Methods, systems, and frameworks for data analytics using machine learning | 2022/9/15 | ||
S48 Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the LIVE-AIR phase 3 randomized double-blind placebo-controlled trial | Z Temesgen CD Burger J Baker C Polk CR Libertin | 2021/11/1 | |
S49 C-reactive protein as a biomarker for improved efficacy of lenzilumab in Covid-19 patients: results from the LIVE-AIR trial | Z Temesgen CD Burger J Baker C Polk CR Libertin | 2021/11/1 | |
C-reactive protein as a biomarker for improved efficacy of lenzilumab in patients with COVID-19: results from the LIVE-AIR trial | Chest | Zelalem Temesgen Charles Burger Jason Baker Christopher Polk Claudia Libertin | 2021/10/1 |
40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial | Open forum infectious diseases | Zelalem Temesgem Charles Burger Jason Baker Christopher Polk Claudia R Libertin | 2021/11 |
Co-Authors
